UA5063U - Способ оценки риска развития бронхолегочных заболеваний - Google Patents
Способ оценки риска развития бронхолегочных заболеваний Download PDFInfo
- Publication number
- UA5063U UA5063U UA20040605174U UA2004605174U UA5063U UA 5063 U UA5063 U UA 5063U UA 20040605174 U UA20040605174 U UA 20040605174U UA 2004605174 U UA2004605174 U UA 2004605174U UA 5063 U UA5063 U UA 5063U
- Authority
- UA
- Ukraine
- Prior art keywords
- risk
- degree
- development
- blz
- content
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000011161 development Methods 0.000 title claims abstract description 17
- 208000027775 Bronchopulmonary disease Diseases 0.000 title claims abstract description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 21
- 229930195729 fatty acid Natural products 0.000 claims abstract description 21
- 239000000194 fatty acid Substances 0.000 claims abstract description 21
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 20
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 22
- 238000001228 spectrum Methods 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 3
- 235000020778 linoleic acid Nutrition 0.000 abstract description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 3
- 150000007513 acids Chemical class 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 description 10
- 230000003859 lipid peroxidation Effects 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 150000001993 dienes Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000037998 chronic venous disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- CLUPOLFGIGLMIQ-UHFFFAOYSA-N heptane;propan-2-ol Chemical compound CC(C)O.CCCCCCC CLUPOLFGIGLMIQ-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Abstract
Предлагаемый способ оценки риска развития бронхолегочных заболеваний заключается в том, что проводят анализ содержания жирных кислот в конденсате выдыхаемого воздуха и, дополнительно, определяют содержание линолевой кислоты и общее содержание полинасыщенных жирных кислот. При отношении содержания линолевой жирной кислоты к общему содержанию полинасыщенных кислот, равном 0,91 … 0,98 диагностируется высокий риск, при отношении 0,84 … 0,90 - средний риск, и при отношении 0,76 … 0,83 - низкий риск бронхолегочных заболеваний.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040605174U UA5063U (ru) | 2004-06-30 | 2004-06-30 | Способ оценки риска развития бронхолегочных заболеваний |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040605174U UA5063U (ru) | 2004-06-30 | 2004-06-30 | Способ оценки риска развития бронхолегочных заболеваний |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA5063U true UA5063U (ru) | 2005-02-15 |
Family
ID=74493876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040605174U UA5063U (ru) | 2004-06-30 | 2004-06-30 | Способ оценки риска развития бронхолегочных заболеваний |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA5063U (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2486522C2 (ru) * | 2011-08-09 | 2013-06-27 | Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) | Способ экспресс-диагностики бронхо-легочных заболеваний |
-
2004
- 2004-06-30 UA UA20040605174U patent/UA5063U/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2486522C2 (ru) * | 2011-08-09 | 2013-06-27 | Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) | Способ экспресс-диагностики бронхо-легочных заболеваний |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klevay et al. | Hair analysis in clinical and experimental medicine | |
| Gaw et al. | Clinical Biochemistry E-Book: An Illustrated Colour Text | |
| US10989633B2 (en) | Method of diluting a metred quantity of a test fluid for analysis | |
| Akizuki | Serum uric acid levels among thirty-four thousand people in Japan. | |
| Kinns et al. | Munchausen syndrome and factitious disorder: the role of the laboratory in its detection and diagnosis | |
| Spivacow et al. | Metabolic risk factors in children with kidney stone disease: an update | |
| Chan et al. | Age‐related changes in bone density, serum parathyroid hormone, calcium absorption and other indices of bone metabolism in Chinese women | |
| Ozdemir et al. | Evaluation of rhabdomyolysis patients who opted for emergency services | |
| Belhadj et al. | Validation of the Tunisian version of the patient health questionnaire (PHQ-9) | |
| UA5063U (ru) | Способ оценки риска развития бронхолегочных заболеваний | |
| Penido et al. | Infantile urolithiasis | |
| Rosengren et al. | Meconium testing for cocaine metabolite: prevalence, perceptions, and pitfalls | |
| RU2726971C1 (ru) | Способ неинвазивной ранней диагностики эндометриоза | |
| Subhani et al. | How to interpret and manage abnormal liver blood test results in older people | |
| Foldenauer et al. | Analysis of exhaled breath condensate in a mixed population of psittacine birds | |
| Rinaldo et al. | Comparison of urinary acylglycines and acylcarnitines as diagnostic markers of medium-chain acyl-CoA dehydrogenase deficiency | |
| Iwata et al. | Urinary trehalase activity as an indicator of kidney injury due to environmental cadmium exposure | |
| JP2009031280A (ja) | 疲労度評価方法およびその利用 | |
| Abdel Gawad et al. | Is serum tryptase a valuable marker for obesity-bronchial asthma interrelationship in children | |
| Higgins et al. | EFFECTS OF CREATINE PRECURSORS IN ARTHRITIS—Clinical and Metabolic Study of Glycocyamine and Betaine | |
| Belhadj et al. | Prevalence of depression in Tunisian general population | |
| Legge | Science digest | |
| RU2388413C1 (ru) | Способ оценки степени тяжести трофологической недостаточности у больных хронической обструктивной болезнью легких | |
| Borgaonkar et al. | Review on evaluation of serum Sodium and serum Potassium in essential Hypertension | |
| Adedeji et al. | Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients |